http://orcid.org/0000-0003-2883-9345
References
- Kumakura S, Ishikura H, Kondo M, et al. Autoimmune-associated hemophagocytic syndrome. Mod Rheumatol Jpn Rheumat Assoc. 2004;14:205–215.
- Henter JI, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–131.
- Larroche C, Mouthon L. Pathogenesis of hemophagocytic syndrome (HPS). Autoimmunity Rev. 2004;3:69–75.
- Kumakura S, Murakawa Y. Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndrome in adults. Arthrit Rheumatol. 2014;66:2297–2307.
- Ideguchi H, Ohno S, Takase K, et al. Successful treatment of refractory lupus-associated haemophagocytic lymphohistiocytosis with infliximab. Rheumatology. 2007;46:1621–1622.
- Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthrit Care Res. 2012;64:797–808.
- Zubair A, Frieri M. Lupus nephritis: review of the literature. Curr Allergy Asthma Rep. 2013;13:580–586.
- Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Internal Med. 2015;162:18–26.
- Canna SW, de Jesus AA, Gouni S, et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nature Genet. 2014;46:1140–1146.
- Ueda Y, Yamashita H, Takahashi Y, et al. Refractory hemophagocytic syndrome in systemic lupus erythematosus successfully treated with intermittent intravenous cyclophosphamide: three case reports and literature review. Clin Rheumatol. 2014;33:281–286.
- Lambotte O, Khellaf M, Harmouche H, et al. Characteristics and long-term outcome of 15 episodes of systemic lupus erythematosus-associated hemophagocytic syndrome. Medicine. 2006;85:169–182.
- Dhote R, Simon J, Papo T, et al. Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. Arthrit Rheumat. 2003;49:633–639.
- Takahashi N, Naniwa T, Banno S. Successful use of etanercept in the treatment of acute lupus hemophagocytic syndrome. Mod Rheumatol/Jpn Rheumat Assoc. 2008;18:72–75.
- Gill DS, Spencer A, Cobcroft RG. High-dose gamma-globulin therapy in the reactive haemophagocytic syndrome. Br J Haematol. 1994;88:204–206.
- Chen RL, Lin KH, Lin DT, et al. Immunomodulation treatment for childhood virus-associated haemophagocytic lymphohistiocytosis. Br J Haematol. 1995;89:282–290.
- Kikuchi H, Yamamoto T, Asako K, et al. Etanercept for the treatment of intractable hemophagocytic syndrome with systemic lupus erythematosus. Mod Rheumatol/Jpn Rheumat Assoc. 2012;22:308–311.
- Bannai E, Yamashita H, Kaneko S, et al. Successful tocilizumab therapy in seven patients with refractory adult-onset Still's disease. Mod Rheumatol/Jpn Rheumat Assoc. 2016;26:297–301.
- Komiya Y, Takenaka K, Nagasaka K. Successful treatment of glucocorticoid and cyclosporine refractory adult-onset Still's disease complicated with hemophagocytic syndrome with plasma exchange therapy and tocilizumab: a case report. Nihon Rinsho Men'eki Gakkai kaishi. 2013;36:478–483.
- Paliga A, Shahbazi N, Gonsalves C, et al. Trilineage myelodysplasia and hemophagocytosis associated with systemic lupus erythematosus. Am J Hematol. 2012;87:529–530.
- Uttenthal BJ, Layton DM, Vyse TJ, et al. Clinical problem-solving. The wolf at the door. N Engl J Med. 2012;366:2216–2221.
- Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85–118.
- Su IJ, Wang CH, Cheng AL, et al. Hemophagocytic syndrome in Epstein-Barr virus-associated T-lymphoproliferative disorders: disease spectrum, pathogenesis, and management. Leuk Lymphoma. 1995;19:401–416.
- Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus. 2005;14:s2–s8.
- Takada H, Ohga S, Mizuno Y, et al. Oversecretion of IL-18 in haemophagocytic lymphohistiocytosis: a novel marker of disease activity. Br J Haematol. 1999;106:182–189.